News

Monash drug discovery researchers have uncovered unexpected information about ‘xanomeline’, a potential-first-in class drug currently progressing through Phase III clinical trials for the treatment of patients with schizophrenia.

Monash University has published a new study to determine the current attitudes of Australian representatives across major and minor political parties, unions, peak organisations and regulatory and clinical bodies towards using psychedelic agents in

Professor Chris Langmead joined a panel of experts at the PSYCH Symposium 2023, Access to Psychedelic Medicines session in London earlier this month.

An international study led by Monash University has, for the first time, harnessed cutting-edge technology to reveal new and unprecedented information of how a special class of drugs work at the M4 muscarinic receptor.

Australia is the world’s first country to legalise the medical use of psychedelics. But not everyone is sure the timing is right. There are still major issues to work out for this move to benefit those most in need.

Professor Chris Langmead is featured in an article in The Age/Sydney Morning Herald on the TGA's medicinal psychedelics decision.

A new Monash biotech company called Phrenix Therapeutics has received funding to advance research to develop new therapeutics for cognitive disorders, particularly in schizophrenia.

In the fight for better mental health services, support and outcomes for millions of people around the world, the data can no longer be ignored: psychedelics might just be the key to unlocking a revolution in mental health.

In this episode of What Happens Next?, Dr Susan Carland talks to Dr Paul Liknaitzky and Dr Meaghan O’Donnell.